Alcon stock might deserve a long look, Barron’s says

Alcon (ALC) is back on the public market after more than eight years under the wing of Swiss drug giant Novartis (NVS) and investors should raise their sights on the stock, Andrew Bary writes in this week’s edition of Barron’s. While Alcon’s business suffered from “some neglect” under Novartis’ control and had lackluster financial results, but that should change now that it is independent, he contends.

https://thefly.com/landingPageNews.php?id=2892195